✦ LIBER ✦

Ruxolitinib for myelofibrosis therapy: current context, pros and cons

✍ Scribed by Pardanani, A

Book ID: 111926019
Publisher: Nature Publishing Group
Year: 2012
Tongue: English
Weight: 141 KB
Volume: 26
Category: Article
ISSN: 0887-6924
DOI: 10.1038/leu.2012.21

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Current framework for DRI development: w

Current framework for DRI development: what are the pros and cons?

✍ Robert M Russell 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 69 KB

Spleen deflation and beyond: The pros an

Spleen deflation and beyond: The pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasms

✍ Alfonso Quintás-Cardama; Srdan Verstovsek 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 784 KB

Pros and Cons of Peginterferon Versus Nu

Pros and Cons of Peginterferon Versus Nucleos(t)ide Analogues for Treatment of Chronic Hepatitis B

✍ Milan J. Sonneveld; Harry L. A. Janssen 📂 Article 📅 2010 🏛 Current Science Inc. 🌐 English ⚖ 165 KB

The emergence of new and more potent treatment options has markedly changed the treatment landscape of chronic hepatitis B. Both peginterferon and nucleos(t)ide analogues have considerable advantages and limitations, and current treatment guidelines refrain from clearly suggesting a first-line treat

Fibrosis Progression and the Pros and Co

Fibrosis Progression and the Pros and Cons of Antiviral Therapy for Hepatitis C Virus Recurrence After Liver Transplantation: A Review

✍ E. De Martin; M. Senzolo; M. Gambato; G. Germani; A. Vitale; F.R. Russo; P. Burr 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 103 KB